While all eyes and ears are focused on COVID-19 and beating this pandemic, the administration has pursued harmful policy changes that we can’t let slip under the radar. In two back-to-back regulatory actions in recent months, the administration has taken steps to make it harder for biopharmaceutical manufacturers to offer assistance to commercially insured patients. Why do these changes matter? Both could lead to patients being forced to pay more out of pocket for their medicines in the middle of a public health and economic crisis, when we should be doing the exact opposite – finding ways to lower costs for patients.
